Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 2Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Lung Neoplasms 3Endometrial Neoplasms 3Neoplasm Metastasis 2Carcinosarcoma 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thoracic Neoplasms 1Stomach Neoplasms 1Salivary Gland Neoplasms 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasms by Site 1Neoplasms 1Myelodysplastic Syndromes 1Melanoma 1Lung Diseases 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Endometrioid 1

Interventions

Carboplatin 25Paclitaxel 24pembrolizumab 22Cyclophosphamide 14Gemcitabine 10Capecitabine 10Doxorubicin 9Specimen Handling 8Nivolumab 8Taxes 7Magnetic Resonance Spectroscopy 7sacituzumab govitecan 6olaparib 6Cisplatin 6eribulin 5durvalumab 5atezolizumab 5Radiotherapy 5Albumin-Bound Paclitaxel 5130-nm albumin-bound paclitaxel 5capivasertib 4Epirubicin 4Docetaxel 4Biopsy 4niraparib 3Vinorelbine 3Radiation 3Fulvestrant 3Blood Specimen Collection 3trastuzumab deruxtecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Triple Negative Breast Neoplasms × ceralasertib × Clear all
NCT03330847 2026-03-10

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

AstraZeneca

Phase 2 Active not recruiting
273 enrolled 22 charts
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡